Shanghai RAAS Blood Products Co Ltd
SZSE:002252

Watchlist Manager
Shanghai RAAS Blood Products Co Ltd Logo
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Watchlist
Price: 7.22 CNY -0.41% Market Closed
Market Cap: 47.9B CNY
Have any thoughts about
Shanghai RAAS Blood Products Co Ltd?
Write Note

Shanghai RAAS Blood Products Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai RAAS Blood Products Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Income from Continuing Operations
ÂĄ1.8B
CAGR 3-Years
4%
CAGR 5-Years
37%
CAGR 10-Years
19%
Beigene Ltd
HKEX:6160
Income from Continuing Operations
-ÂĄ6.7B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Income from Continuing Operations
-ÂĄ1.3B
CAGR 3-Years
3%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Income from Continuing Operations
ÂĄ1.2B
CAGR 3-Years
22%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Income from Continuing Operations
ÂĄ3.7B
CAGR 3-Years
-26%
CAGR 5-Years
12%
CAGR 10-Years
39%
Imeik Technology Development Co Ltd
SZSE:300896
Income from Continuing Operations
ÂĄ1.9B
CAGR 3-Years
62%
CAGR 5-Years
74%
CAGR 10-Years
N/A
No Stocks Found

Shanghai RAAS Blood Products Co Ltd
Glance View

Market Cap
48B CNY
Industry
Biotechnology

Shanghai RAAS Blood Products Co., Ltd. is a key player in China's biopharmaceutical landscape, specializing in the production and supply of human blood products and diagnostic reagents. Founded in 1992, the company has grown to become one of the largest blood product manufacturers in the country, serving the increasing demand for high-quality and safe blood-derived therapies. The company’s extensive portfolio includes a range of products such as human albumin, immunoglobulins, and coagulants, which are essential for treating various medical conditions, from trauma care to chronic diseases. With a strong commitment to innovation and quality, RAAS has established robust research and development capabilities, ensuring that it stays at the forefront of advancements in blood product technologies. For investors, Shanghai RAAS represents a compelling opportunity in the rapidly expanding Chinese healthcare market. The company operates in a highly regulated environment, giving it a competitive edge through rigorous quality control and adherence to international standards. Furthermore, as China’s aging population grows and healthcare spending increases, the demand for reliable blood products is expected to rise significantly. RAAS has strategically positioned itself to capture this market growth, supported by a diversified customer base that includes hospitals and medical institutions. With its commitment to sustainability, innovation, and shareholder value, investing in Shanghai RAAS not only aligns with a growing industry but also offers the potential for solid returns as the company continues to expand its footprint in both domestic and international markets.

Intrinsic Value
9.13 CNY
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Shanghai RAAS Blood Products Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
1.8B CNY

Based on the financial report for Sep 30, 2024, Shanghai RAAS Blood Products Co Ltd's Income from Continuing Operations amounts to 1.8B CNY.

What is Shanghai RAAS Blood Products Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
19%

Over the last year, the Income from Continuing Operations growth was -11%. The average annual Income from Continuing Operations growth rates for Shanghai RAAS Blood Products Co Ltd have been 4% over the past three years , 37% over the past five years , and 19% over the past ten years .

Back to Top